At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed May 6, 2026 at 18:00 ET
Revolution Medicines announced that Phase 1/2 data for daraxonrasib in RAS-mutant pancreatic cancer were published in NEJM, complementing recently reported positive Phase 3 topline results showing an unprecedented overall survival benefit. The drug holds FDA Breakthrough Therapy and Orphan Drug Designations, reinforcing its potential as a new standard of care for a deadly cancer with limited treatment options.
- NEJM published Phase 1/2 data for daraxonrasib in metastatic RAS-mutant PDAC.
- Company previously announced positive Phase 3 RASolute 302 topline results with unprecedented overall survival benefit vs. standard chemotherapy.
- Daraxonrasib has FDA Breakthrough Therapy and Orphan Drug Designations for PDAC with G12 mutations.
- Daraxonrasib is a RAS(ON) multi-selective inhibitor targeting diverse RAS mutations.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access